Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 1;17(2):170-172.
doi: 10.1097/ICB.0000000000001140.

OFFICE MANAGEMENT OF OZURDEX IMPLANT DISLOCATION INTO THE ANTERIOR CHAMBER

Abhimanyu S Ahuja  1 , Jude A Jaraki  1 , Lawrence S Halperin  1   2
Affiliations

OFFICE MANAGEMENT OF OZURDEX IMPLANT DISLOCATION INTO THE ANTERIOR CHAMBER

Abhimanyu S Ahuja et al. Retin Cases Brief Rep. .

Abstract

Purpose: To describe a novel office procedure that permits the repositioning of an Ozurdex implant from the anterior chamber back into the vitreous cavity.

Methods: Description of an office technique for Ozurdex repositioning using a 30-gauge needle.

Results: In both cases, the Ozurdex implant was successfully returned to the vitreous cavity. In Case 1, the patient's visual acuities 1 and 2 weeks after this were 20/70 and 20/40, respectively, and had no further complications. In Case 2, the patient returned 1 week later, with the implant remaining posterior and a visual acuity of 20/40.

Conclusion: The success of this novel technique in these cases demonstrates the potential to avoid a surgical procedure in the event of Ozurdex implant migration to the anterior chamber, while at the same time allowing the Ozurdex implant to remain effective in the eye.

PubMed Disclaimer

References

    1. Haller JA, Bandello F, Belfort R Jr, et al.; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexameth- asone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134–1136.
    1. Lowder C, Belfort R Jr, Lightman S, et al.; Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfec- tious intermediate or posterior uveitis. Arch Ophthalmol 2011;129:545–553.
    1. Boyer DS, Yoon YH, Belfort R, et al. Three-year, randomized, sham- controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014;121:1904–1914.
    1. Ozurdex [Package Insert]. Irvine, CA: Allergan Inc; 1958.
    1. Röck D, Bartz-Schmidt KU, Röck T. Risk factors for and management of anterior chamber intravitreal dexamethasone implant migration. BMC Ophthalmol 2019;19:120.

LinkOut - more resources